Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Breast Neoplasms 6Neoplasm Metastasis 5Nasopharyngeal Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 2Neoplasms 2Malnutrition 2Colonic Neoplasms 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrent Squamous Cell Lung Carcinoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nonsquamous Nonsmall Cell Neoplasm of Lung 1Neurotoxicity Syndromes 1Neoplastic Cells, Circulating 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Lung Neoplasms 1Liver Neoplasms 1Gallbladder Neoplasms 1Fatigue 1Esophageal Neoplasms 1Chemotherapy-induced Peripheral Neuropathy 1CYP3A Phenotyping 1Biliary Tract Neoplasms 1

Interventions

enzalutamide 2Docetaxel 1Blood Specimen Collection 1Biopsy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Metastatic Castration Resistant Prostate Cancer × Docetaxel × Clear all
NCT03328364 2024-11-21

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

Astellas Pharma Inc

Completed
211 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡